Description
Provider of medical research services. The company is engaged in biotechnology and pharmaceutical research specially in the field of gastrointestinal diseases with the intent to develop probiotic treatments.
Contact Information
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2011253984-A1 | Method for identifying e. coli m-17 | Abandoned | 07-Dec-2010 | 000000000 | |
US-20120183960-A1 | Method for identifying e. coli m-17 | Abandoned | 07-Dec-2010 | 000000000 | |
EP-2463382-A1 | Method for identifying e. coli m-17 | Withdrawn | 07-Dec-2010 | 000000000 | 00 |
CA-2652558-A1 | Bacterial strains, compositions including same and probiotic use thereof | Abandoned | 18-May-2006 | 0000000000 | |
JP-2009537138-A | Bacterial strain, composition containing this bacterial strain and its probiotic use | Pending | 18-May-2006 | A23L33/135 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Richard Lanzara Ph.D | Owner, Principal Scientific Officer & President |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000 0000 0000 | 02-Jan-2003 | 0000000000 | Elder and Disabled Care |